Snapshot from Sep 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Business earnings release

Tigermed 2026 Interim Results

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 28, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The strong interim results, with revenue and profit growth, are likely to positively impact Tigermed's stock price and investor sentiment. The strategic partnerships and acquisitions signal expansion and capability enhancement, potentially strengthening its competitive position in the CRO market.

Pharmaceutical Biotechnology Healthcare

Hangzhou Tigermed Consulting Co., Ltd., a leading global CRO, announced its 2026 interim results on August 28, 2026. Revenue grew 14.1% YoY to RMB 3,707.6 million, with adjusted net profit up 31.8% to RMB 277.7 million. The company signed strategic cooperation agreements with Hisun Pharmaceutical, Insilico Medicine, 3SBio, and a European multinational, completed acquisitions of Teddy Laboratory and Shanghai Bioquick, and opened its new global headquarters in Hangzhou. Tigermed expanded its global footprint, establishing a subsidiary in New Zealand and commencing operations at a CDMO facility in the U.S. The company also advanced AI integration in clinical research, developing an intelligent platform and SAP system. Management expressed optimism about the recovering biopharmaceutical industry and continued globalization of China's innovative medicines.

70 Hangzhou Tigermed Consulting signed agreements
50 Hangzhou Tigermed Consulting commenced operations
45 Hangzhou Tigermed Consulting established subsidiary
40 Hangzhou Tigermed Consulting opened headquarters
40 Hangzhou Tigermed Consulting developed SAP system
30 Hangzhou Tigermed Consulting published report
stock
Central entity; reported strong financial results and strategic expansions, boosting its market position.
Importance 100.0 Sentiment 70.0
cnt
Tigermed's home market; revenue grew 24% YoY, reflecting strong domestic demand.
Importance 50.0 Sentiment 60.0
cnt
Key overseas market; Tigermed expanded operations with new CDMO facility and increased clinical trial projects.
Importance 40.0 Sentiment 50.0
stock
Signed strategic cooperation agreement with Tigermed, deepening collaboration in clinical trials and early-stage R&D.
Importance 40.0 Sentiment 50.0
priv
Signed strategic cooperation agreement with Tigermed, focusing on AI enablement in drug development.
Importance 40.0 Sentiment 50.0
stock
Signed strategic cooperation agreement with Tigermed, enhancing collaboration in clinical trials.
Importance 40.0 Sentiment 50.0
stock
Acquired Teddy Laboratory, expanding its laboratory services capabilities.
Importance 30.0 Sentiment 40.0
priv
Acquired by Tigermed/Frontage, enhancing preclinical R&D and laboratory testing capabilities.
Importance 30.0 Sentiment 40.0
priv
Acquired by Tigermed, strengthening clinical supply chain capabilities.
Importance 30.0 Sentiment 40.0
per
Co-founder and Chairman; commented on industry recovery and company strategy.
Importance 30.0 Sentiment 50.0
cnt
New clinical project orders grew nearly 100% YoY, indicating strong growth.
Importance 20.0 Sentiment 40.0
cnt
Tigermed established end-to-end service solutions in South Korea.
Importance 20.0 Sentiment 40.0
cnt
Tigermed established end-to-end service solutions in Japan.
Importance 20.0 Sentiment 40.0
govactor
Co-published a report on DCT industry practice with Tigermed.
Importance 20.0 Sentiment 30.0
priv
Co-published a report on DCT industry practice with Tigermed.
Importance 20.0 Sentiment 30.0
+ 6 more entities View on Dashboard
China strategic rivals ↔ United States China views the United States as a strategic rival, characterized by ongoing trade disputes, technological competition,
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.